Evotec AG has completed the sale of its chemical development business, which includes an active pharmaceutical ingredient (API) facility in Oxford, UK, and a parenteral, fill-finish facility in Glasgow, UK, to Aptuit Inc. of the United States for a consideration of £31.5 million.
Addex Pharmaceuticals SA and Merck, Sharp and Dohme Research Ltd, an affiliate of Merck & Co, have entered into an exclusive collaboration and licensing agreement to develop a new class of ingested drugs that potentially will treat Parkinson’s disease and other diseases.
e-Therapeutics, which uses informatics for discovering the safety and efficacy of new combinations or applications of existing medical compounds, has received a listing on the Alternative Investment Market (AIM) of the London Stock Exchange.
Exiqon A/S, a Danish supplier of gene-expression analysis products, is acquiring California-based Oncotech Inc, which markets diagnostic tests to optimise drug-treatment selection for cancer patients.
Companies that wish to develop drugs for rare or life-threatening diseases can now apply for financial incentives from the US and the European Union (EU) using a single application form.
Pronova BioPharma ASA, which was listed on the Oslo Stock Exchange in October 2007, is likely to benefit from the planned $1.65 billion acquisition by GlaxoSmithKline Plc (GSK) of Reliant Pharmaceuticals Inc.
Children who are diagnosed with cancer have the same prospect for survival as a parent who was also diagnosed with the same cancer.
Photocure ASA, a Norwegian company that has developed a photosensitive method of killing cancer cells, is ‘de-merging’ its 91.4%-owned subsidiary, PCI Biotech, by distributing shares in the subsidiary to its existing shareholders on a one-for-one basis.
Hybrigenics SA, a French proteomics specialist with a drug candidate in Phase 2 development for treating prostate cancer, is raising between €24.2 million and €28.1 million in an initial public offering (IPO) of its shares on the Alternext section of the Euronext Paris stock exchange.
Antisoma Plc said its lead cancer compound, ASA404 will enter Phase 3 for lung cancer in early 2008.